L'immunoscintigraphie par les anticorps monoclonaux radiomarqués. Evolution d'une méthode de diagnostic du cancer et espoir d'une nouvelle forme de thérapie [Immunoscintigraphy using radio-labeled monoclonal antibodies. Development of a method of cancer diagnosis and hopes for a new form of therapy].

Détails

ID Serval
serval:BIB_FEA349618017
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
L'immunoscintigraphie par les anticorps monoclonaux radiomarqués. Evolution d'une méthode de diagnostic du cancer et espoir d'une nouvelle forme de thérapie [Immunoscintigraphy using radio-labeled monoclonal antibodies. Development of a method of cancer diagnosis and hopes for a new form of therapy].
Périodique
Schweizerische Medizinische Wochenschrift
Auteur(s)
Mach J.P., Bischof-Delaloye A., Curchod S., Studer A., Grob J.P., Volant J.C., Mosimann F., Givel J.C., Douglas P., Leyvraz S.
ISSN
0036-7672 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
1987
Peer-reviewed
Oui
Volume
117
Numéro
29
Pages
1076-1086
Langue
français
Résumé
Personal results are presented to illustrate the development of immunoscintigraphy for the detection of cancer over the last 12 years, from the early experimental results in nude mice grafted with human colon carcinoma to the most modern form of immunoscintigraphy applied to patients, using I123 labeled Fab fragments from monoclonal anti-CEA antibodies detected by single photon emission computerized tomography (SPECT). The first generation of immunoscintigraphy used I131 labeled, immunoadsorbent purified, polyclonal anti-CEA antibodies and planar scintigraphy, as the detection system. The second generation used I131 labeled monoclonal anti-CEA antibodies and SPECT, while the third generation employed I123 labeled fragments of monoclonal antibodies and SPECT. The improvement in the precision of tumor images with the most recent forms of immunoscintigraphy is obvious. However, we think the usefulness of immunoscintigraphy for routine cancer management has not yet been entirely demonstrated. Further prospective trials are still necessary to determine the precise clinical role of immunoscintigraphy. A case report is presented on a patient with two liver metastases from a sigmoid carcinoma, who received through the hepatic artery a therapeutic dose (100 mCi) of I131 coupled to 40 mg of a mixture of two high affinity anti-CEA monoclonal antibodies. Excellent localisation in the metastases of the I131 labeled antibodies was demonstrated by SPECT and the treatment was well tolerated. The irradiation dose to the tumor, however, was too low at 4300 rads (with 1075 rads to the normal liver and 88 rads to the bone marrow), and no evidence of tumor regression was obtained. Different approaches for increasing the irradiation dose delivered to the tumor by the antibodies are considered.
Mots-clé
Animals, Antibodies, Monoclonal/diagnostic use, Antibodies, Monoclonal/therapeutic use, Carcinoembryonic Antigen/immunology, Colonic Neoplasms/radionuclide imaging, Humans, Iodine Radioisotopes/diagnostic use, Iodine Radioisotopes/therapeutic use, Liver Neoplasms/radiotherapy, Liver Neoplasms/secondary, Male, Mice, Mice, Nude, Middle Aged, Neoplasm Transplantation, Neoplasms, Experimental/radionuclide imaging, Sigmoid Neoplasms, Tomography, Emission-Computed
Pubmed
Web of science
Création de la notice
28/01/2008 8:32
Dernière modification de la notice
20/08/2019 16:29
Données d'usage